Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prezalumab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Prezalumab (AMG 557) is a fully human IgG2 monoclonal antibody developed for the treatment of autoimmune diseases. It specifically targets and inhibits the function of inducible T-cell co-stimulator ligand (ICOSL), also known as B7-related protein 1 (B7RP-1), thereby modulating T cell activation and immune responses. The drug was primarily investigated for systemic lupus erythematosus (SLE), Sjogren's syndrome, cutaneous lupus erythematosus, and psoriasis. Prezalumab was developed by Amgen in partnership with MedImmune/AstraZeneca but has been discontinued in all indications[4][6][3][5]. Its mechanism involves blocking the interaction between ICOSL on antigen-presenting cells and ICOS on activated T cells to reduce pathological immune activation[6][2].
- Other names
- prezalumabAMG 557AMG557AMG-557B7RP-1 mAbB-7RP-1 mAbB 7RP-1 mAbMEDI-5872MEDI5872MEDI 5872
02
Targets
ICOSLG (Inducible T-cell Co-stimulator Ligand)
Beyond the preview
Go deeper on prezalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prezalumab.